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 with more emerging aimed at "mental performance"
 and sports, for example-the arguments given by de
 Jong and colleagues for postlaunch monitoring are
 sound.3 Such monitoring could take a second look at
 need and synergistic effects, a research direction raised
 by the impact of food colourings, for example, which
 are used extensively in food and soft drinks."
 If evidence is robust that these products improve
 health, then what was wrong with people's diets in the
 first place?'2 Attention to global nutrition has histori
 cally been on underconsumption, but more recently the
 reliance on preprocessed foods in industrialised society
 means that obesity has also become a problem.'3 So
 where do functional foods fit? Are they the first phase
 of fine tuning the consequences of the industrialised diet
 and lifestyle?'4 Or are they part of the wider struggle to
 improve diet in populations, which the WHO and Food
 and Agriculture Organization championed in 2004?'5
 Proponents argue that functional foods and drinks
 allow people to eat and drink more healthily without
 radically changing their diet.2 Certainly, big changes in
 diet are needed.'3 Functional foods and drinks may be
 legal, make money, and reshape the way we think about
 food and drink. However, at best they are likely to be
 technical fixes, and at worst, another confounding factor
 that nutritional epidemiologists will have to unravel for
 years to come.
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 Patients with multiple conditions are the rule rather than
 the exception in primary care.' In a recent study of 21
 family practices in the Saguenay region, Quebec, the
 prevalence of multimorbidity was 69% in 18-44 year
 olds, 93% in 45-64 year olds, and 98% in those aged over
 65, and the number of chronic conditions varied from
 2.8 in the youngest to 6.4 in the oldest.' Other countries
 report a similar burden. 3 The number of Americans
 with multimorbidity is estimated to rise from 60 million
 in 2000 to 81 million by 2020.4
 Having multiple chronic medical conditions is associ
 ated with poor outcomes: patients have decreased qual
 ity of life,= psychological distress," longer hospital stays,
 more postoperative complications, a higher cost of care,
 and higher mortality. Multimorbidity also affects pro
 cesses of care and may result in complex self care needs7;
 challenging organisational problems (accessibility, coor
 dination, consultation time); polypharmacy; increased
 use of emergency facilities; difficulty in applying guide
 lines; and fragmented, costly, and ineffective care.
 Yet most research and clinical practice is still based on
 a single disease paradigm which may not be appropriate
 for patients with complex and overlapping health prob
 lems. Classic clinical trials tend to emphasise efficacy at
 the expense of effectiveness. In doing so, they exclude
 patients with multiple conditions, thereby compromis
 ing the external validity and the relevance of the trials
 for this population.8
 Research on multimorbidity is in its infancy.9 So
 far, most research has investigated the epidemiology
 of multimorbidity, its effect on physical functioning,
 and its measurement. Much less studied is the effect of
 multimorbidity on processes of care and what consti
 tutes "best care" for these patients.
 Areas for potential investigation of multimorbidity
 fall primarily into three categories-defining and cate
 gorising the population; developing the tools needed to
 explore multimorbidity and its consequences; and using
 these tools to investigate promising processes of care.
 Who are the patients with several conditions? What is
 their risk profile? How do we distinguish multimorbidity
 from related concepts such as complexity, frailty, and
 polypharmacy? How do we classify multimorbidity and
 comorbidity in terms of conditions that need disparate
 versus congruent treatment strategies? For example,
 how does the patient with coronary disease, hyperten
 sion, and diabetes differ from the one with pulmonary
 disease, arthritis, and depression? In which situations is
 a subjective or an objective measure of multimorbidity
 more appropriate? Investigators have begun to look at
 several of these complex questions, but standards have
 not yet been developed.'(
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 The results of prevalence studies reveal a complex
 picture of coexisting diseases. We now require a clear
 conceptual framework that includes consistent measures
 of multimorbidity and permits comparisons between
 studies. This will facilitate the next step-investigating
 improved processes of care. What are the best processes
 for making decisions in the context of multiple, often ill
 defined, problems and fragmentary evidence?" How
 should we assess the shifting priorities of patients and
 providers, design adaptive responses to unpredictable
 aspects of the illnesses, and organise multiple resources
 to achieve specific health goals?" What affects processes
 of care, and what constitutes best care? Which outcomes
 matter to these patients in which situations? How do we
 implement whatever best care turns out to be?
 Answers to these questions will require continual
 experimentation, with substantial innovation and reform
 in healthcare delivery and organisation. Models of col
 laborative, patient centered, and goal oriented care are
 more likely to meet the complex needs of patients with
 multimorbidity. Involving patients in the research pro
 cess and making good use of mixed methods research
 designs that incorporate both patient and provider
 perspectives may also help answer complex clinical
 questions.
 The study of multimorbidity is particularly appropri
 ate for the international research community for sev
 eral reasons. Research is in its infancy, and appropriate
 collaboration may minimise redundancy and promote
 efficient and timely research. Different international
 communities have varied access to administrative data
 that can be used to paint broad pictures of caring for
 people with several conditions. The World Health
 Organization has given priority during the next decade
 to worldwide prevention and care of chronic illness.'2
 International collaboration specifically among primary
 care researchers may result in patient centered and low
 tech care practices that can be translated into practice in
 varied settings and across different healthcare systems.
 As a step towards facilitating this collaboration, we
 have started a virtual research community to discuss
 research questions specifically directed towards inter
 national communication on multimorbidity (www.med.
 usherbrooke.ca/cirmo/). The increasing number of
 primary care research networks in many countries also
 offers an ideal setting for collaboration to occur. The
 time has come not only to include people of all ages
 with multimorbidity in research efforts, but to focus
 on improving the care of this vulnerable and growing
 population.
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 The evidence that pharmacological thromboprophy
 laxis can reduce the rate of venous thromboembolism
 by 60-65% is compelling.'3 Last month the United
 Kingdom's National Institute for Health and Clinical
 Excellence (NICE) published guidelines on venous
 thromboembolism in patients having surgical proce
 dures,4 which are summarised in this week's BMJ5 The
 risks to surgical patients, particularly those undergoing
 orthopaedic procedures, are well known, but most
 people who develop venous thromboembolism in
 hospital are medical patients.
 The prevention of venous thromboembolism in adult
 patients in hospital was the main challenge to patient
 safety in 2001, according to a technical assessment by
 the Agency for Healthcare Research and Quality in the
 United States.() In 2005, the UK government's Health
 Select Committee reported that venous thromboembo
 lism caused more than 25 000 potentially preventable
 deaths a year, and probably half of these deaths resulted
 from admission to hospital.7
 Despite all this evidence, mortality due to venous
 thromboembolism after hospital admission is still at
 least 10 times greater than the more widely publicised
 mortality due to methicillin resistant Staphylococcus aureus
 (MRSA). Overall, the number of deaths from venous
 thromboembolism in the UK each year is five times
 greater than the combined total number of deaths from
 breast cancer, AIDS, and road traffic incidents. Indeed
 a revised estimate, based on an epidemiological model
 using extrapolation from European data, suggests that
 about 60000 deaths from venous thromboembolism
 occur annually in the UK.8 Autopsy data indicate that
 about 10% of deaths in hospital are due to pulmonary
 embolism."
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